[Corrigendum] Azurocidin 1 inhibits the aberrant proliferation of triple‑negative breast cancer through the regulation of pyroptosis

• Authors:
  • Shanshan Lei
  • Shutong Li
  • Weiwei Xiao
  • Qiuping Jiang
  • Shifan Yan
  • Wen Xiao
  • Jiaodi Cai
  • Jingjing Wang
  • Lianhong Zou
  • Fang Chen
  • Yanjuan Liu
  • Yu Jiang

• View Affiliations

  
  Affiliations: Department of Emergency, Institute of Emergency Medicine, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan 410000, P.R. China, 2Department of Breast and Thyroid Surgery, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan 410000, P.R. China, Department of Pathology, The Fourth Hospital of Changsha, The Affiliated Changsha Hospital of Hunan Normal University, Changsha, Hunan 410000, P.R. China
• Published online on: January 24, 2024     https://doi.org/10.3892/or.2024.8708
• Article Number: 49

• Copyright : © Lei et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Article

Oncol Rep 50: [Related article:] 188, 2023; DOI: 10.3892/or.2023.8625

Following the publication of the above article, the authors drew to our attention that they had made a couple of inadvertent errors in assembling Figs. 4 and 5; first, for the BT-549 cell line, the data shown for the Pro-caspase-1/Cleaved caspase-1 in Fig. 5 and the GSDMD-F/GSDMD-N data in Fig. 4B were identical, and had been derived from the same original source; secondly, in Fig. 4A, the data shown correctly for the GSDMD BT-549 cell line had also inadvertently been included in this figure to represent the MDA-MB-231 cell line.

Figure 4. GSDMD protein level is detected in TNBC cell lines with exogenous AZU1 stimuli using western blot analysis. (A) GSDMD protein level in TNBC cell lines treated with 500 ng/ml AZU1 at different time points. **P<0.01 and ***P<0.001; (n=3). (B) GSDMD protein level in TNBC cell lines treated with different concentrations of AZU1. *P<0.05, **P<0.01 and ***P<0.001; (n=3). GSDMD, gasdermin D; TNBC, triple-negative breast cancer; AZU1, azurocidin 1.

Figure 5. Western blot analysis is conducted to investigate the protein expression levels of p-p65, p65, NLRP3, pro-caspase-1, cleaved caspase-1 and ASC in TNBC cell lines with exogenous AZU1 stimuli. *P<0.05, **P<0.01 and ***P<0.001; (n=3). NLRP3, NLR family pyrin domain containing 3; ASC, apoptosis-associated speck-like protein containing a CARD; TNBC, triple-negative breast cancer; AZU1, azurocidin 1.

The revised and corrected versions of Figs. 4 and 5, showing the correct western blotting data for the GSDMD experiment in Fig. 4A and the Pro-caspase-1/Cleaved caspase-1 data for the BT-549 cell line in Fig. 5, are shown in the next two pages. The authors regret that these errors in the assembly of Figs. 4 and 5 went unnoticed before the article was published, and thank the Editor of Oncology Reports for granting them the opportunity to publish this corrigendum. All the authors agree with the publication of this corrigendum; furthermore, they apologize to the readership of the journal for any inconvenience caused.